+

WO2004090551A3 - Especes de polypeptides secretes associees a des troubles cardio-vasculaires - Google Patents

Especes de polypeptides secretes associees a des troubles cardio-vasculaires Download PDF

Info

Publication number
WO2004090551A3
WO2004090551A3 PCT/EP2004/003737 EP2004003737W WO2004090551A3 WO 2004090551 A3 WO2004090551 A3 WO 2004090551A3 EP 2004003737 W EP2004003737 W EP 2004003737W WO 2004090551 A3 WO2004090551 A3 WO 2004090551A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disorders
secreted polypeptide
species associated
polypeptide species
polypeptides
Prior art date
Application number
PCT/EP2004/003737
Other languages
English (en)
Other versions
WO2004090551A2 (fr
Inventor
Guilaine Argoud-Puy
Nassima Bederr
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Original Assignee
Genova Ltd
Novartis Pharma Gmbh
Guilaine Argoud-Puy
Nassima Bederr
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genova Ltd, Novartis Pharma Gmbh, Guilaine Argoud-Puy, Nassima Bederr, Lydie Bougueleret, Isabelle Cusin, Eve Mahe, Anne Niknejad, Samia Reffas filed Critical Genova Ltd
Priority to EP04726116A priority Critical patent/EP1616194A2/fr
Priority to US10/550,632 priority patent/US20070128664A1/en
Priority to JP2006505052A priority patent/JP2006523191A/ja
Publication of WO2004090551A2 publication Critical patent/WO2004090551A2/fr
Publication of WO2004090551A3 publication Critical patent/WO2004090551A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

L'invention concerne des polypeptides humains sécrétés circulant à un taux accru dans le plasma de patients souffrant de troubles cardio-vasculaires. L'invention concerne également des procédés d'utilisation de compositions renfermant les polypeptides, des polynucléotides codant ceux-ci et des anticorps spécifiques de ces polypeptides, aux fins de diagnostic, de pronostic et de développement de médicaments.
PCT/EP2004/003737 2003-03-31 2004-04-07 Especes de polypeptides secretes associees a des troubles cardio-vasculaires WO2004090551A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04726116A EP1616194A2 (fr) 2003-04-08 2004-04-07 Especes de polypeptides secretes associees a des troubles cardio-vasculaires
US10/550,632 US20070128664A1 (en) 2003-03-31 2004-04-07 Secreted polypeptide species associated with cardiovascular disorders
JP2006505052A JP2006523191A (ja) 2003-04-08 2004-04-07 心臓血管障害に関連する分泌ポリペプチド種

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US46155803P 2003-04-08 2003-04-08
US46162303P 2003-04-08 2003-04-08
US60/461,558 2003-04-08
US60/461,623 2003-04-08
US47147903P 2003-05-16 2003-05-16
US60/471,479 2003-05-16
US47486303P 2003-05-30 2003-05-30
US60/474,863 2003-05-30
US48414003P 2003-06-30 2003-06-30
US60/484,140 2003-06-30

Publications (2)

Publication Number Publication Date
WO2004090551A2 WO2004090551A2 (fr) 2004-10-21
WO2004090551A3 true WO2004090551A3 (fr) 2005-01-20

Family

ID=33163255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003737 WO2004090551A2 (fr) 2003-03-31 2004-04-07 Especes de polypeptides secretes associees a des troubles cardio-vasculaires

Country Status (3)

Country Link
EP (1) EP1616194A2 (fr)
JP (1) JP2006523191A (fr)
WO (1) WO2004090551A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523844A (ja) * 2003-04-25 2007-08-23 ジェノバ・リミテッド 心臓血管障害において減少する分泌ポリペプチド種
FI118265B (fi) * 2004-01-15 2007-09-14 Jurilab Ltd Oy Menetelmä akuutin sydäninfarktin ja sepelvaltimotaudin riskin havaitsemiseksi
JP2013076691A (ja) * 2011-09-12 2013-04-25 Taisho Pharmaceutical Co Ltd 疲労バイオマーカー

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017807A1 (fr) * 1996-10-17 1998-04-30 Meristem Therapeutics S.A. Lipases pancreatiques et/ou colipases recombinantes et polypeptides derives produits par les plantes, leurs procedes d'obtention et leurs utilisations
WO1998030588A1 (fr) * 1997-01-07 1998-07-16 Laboratoire Laphal (Laboratoire De Pharmacologie Appliquee) Inhibiteurs specifiques de la lipase pancreatique et leurs applications
WO2002006840A2 (fr) * 2000-07-13 2002-01-24 Biopreventive Ltd. Procede non vulnerant et rapide de diagnostic differentiel d'affection cardiaque aigue
US6503540B1 (en) * 1999-03-25 2003-01-07 David E. Reese Cloning and characterization of bves, a novel gene expressed in heart and uses thereof
WO2003023397A1 (fr) * 2001-09-12 2003-03-20 National Research Council Of Canada Methode pour la determination simultanee et directe du cholesterol serique dans les lipoproteines de haute et de basse densite au moyen d'une spectroscopie infrarouge

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017807A1 (fr) * 1996-10-17 1998-04-30 Meristem Therapeutics S.A. Lipases pancreatiques et/ou colipases recombinantes et polypeptides derives produits par les plantes, leurs procedes d'obtention et leurs utilisations
WO1998030588A1 (fr) * 1997-01-07 1998-07-16 Laboratoire Laphal (Laboratoire De Pharmacologie Appliquee) Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US6503540B1 (en) * 1999-03-25 2003-01-07 David E. Reese Cloning and characterization of bves, a novel gene expressed in heart and uses thereof
WO2002006840A2 (fr) * 2000-07-13 2002-01-24 Biopreventive Ltd. Procede non vulnerant et rapide de diagnostic differentiel d'affection cardiaque aigue
WO2003023397A1 (fr) * 2001-09-12 2003-03-20 National Research Council Of Canada Methode pour la determination simultanee et directe du cholesterol serique dans les lipoproteines de haute et de basse densite au moyen d'une spectroscopie infrarouge

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAPUS C ET AL: "ROLE OF COLIPASE IN THE INTERFACIAL ADSORPTION OF PANCREATIC LIPASEAT HYDROPHILIC INTERFACES", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 58, no. 1, 1 October 1975 (1975-10-01), pages 155 - 158, XP002041838, ISSN: 0014-5793 *
MAHE-GOUHIER N ET AL: "IMMOBILIZED COLIPASE AFFINITIES FOR LIPASES B, A, C AND THEIR TERMINAL PEPTIDE (336-449): THE LIPASE RECOGNITION SITE LYSINE RESIDUES ARE LOCATED IN THE C-TERMINAL REGION", BBA - LIPIDS AND LIPID METABOLISM, ELSEVIER SCIENCE BV. AMSTERDAM, NL, vol. 962, 1988, pages 91 - 97, XP002041839, ISSN: 0005-2760 *

Also Published As

Publication number Publication date
WO2004090551A2 (fr) 2004-10-21
EP1616194A2 (fr) 2006-01-18
JP2006523191A (ja) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2004047755A3 (fr) Heterocycles contenant de l'azote bicyclique fusionne
ZA200701656B (en) Humanized anti-cment antagonists
WO2004098377A3 (fr) Procedes et compositions pour le diagnostic et la therapie de troubles lies a la parkine
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2002074156A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2007059135A3 (fr) Procedes destines a traiter la maladie d’alzheimer
WO2004050017A3 (fr) Anticorps elabores de maniere rationnelle
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2004002431A3 (fr) Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2005015206A3 (fr) Espece de polypeptides secretes associee aux troubles cardiovasculaires
WO2005014635A3 (fr) Especes de polypeptides secretes reduites dans les affections cardio-vasculaires
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2006068987A3 (fr) Utilisations de cytokine mammalienne, reactifs associes
WO2004106941A3 (fr) Especes de polypeptides secretes associees a des troubles cardio-vasculaires
WO2005058251A3 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2005030266A3 (fr) Imagerie optique du cancer colorectal
WO2004090551A3 (fr) Especes de polypeptides secretes associees a des troubles cardio-vasculaires
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2005003781A3 (fr) Especes de polypeptides secretes associes a des troubles cardiovasculaires
WO2004101615A3 (fr) Especes de polypeptides secretes associes aux troubles cardio-vasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004726116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006505052

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004726116

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007128664

Country of ref document: US

Ref document number: 10550632

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10550632

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载